Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APVO OTCMKTS:CRPOF NASDAQ:GHSI OTCMKTS:MCUJF NASDAQ:UMRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$4.67$4.89$3.80▼$91.44$5.82M1.6832,855 shs16,520 shsCRPOFCeapro$0.17$0.17$0.11▼$0.40$13.31M1.4715,466 shsN/AGHSIGuardion Health Sciences$3.22$3.24$3.04▼$18.00$4.35M0.73105,261 shsN/AMCUJFMedicure$0.67$0.82$0.67▼$0.97$7.04M0.98482 shsN/AUMRXCogent Biosciences$36.95+3.7%$10.50$0.29▼$3.72$1.57B3.931.22 million shs2.23 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics0.00%-2.30%-7.34%+3.62%-94.94%CRPOFCeapro0.00%0.00%0.00%0.00%0.00%GHSIGuardion Health Sciences0.00%0.00%0.00%0.00%0.00%MCUJFMedicure0.00%-17.37%-16.08%-16.15%-17.73%UMRXCogent Biosciences0.00%0.00%0.00%+10.70%+384.91%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPVOAptevo Therapeutics$4.67$4.89$3.80▼$91.44$5.82M1.6832,855 shs16,520 shsCRPOFCeapro$0.17$0.17$0.11▼$0.40$13.31M1.4715,466 shsN/AGHSIGuardion Health Sciences$3.22$3.24$3.04▼$18.00$4.35M0.73105,261 shsN/AMCUJFMedicure$0.67$0.82$0.67▼$0.97$7.04M0.98482 shsN/AUMRXCogent Biosciences$36.95+3.7%$10.50$0.29▼$3.72$1.57B3.931.22 million shs2.23 million shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPVOAptevo Therapeutics0.00%-2.30%-7.34%+3.62%-94.94%CRPOFCeapro0.00%0.00%0.00%0.00%0.00%GHSIGuardion Health Sciences0.00%0.00%0.00%0.00%0.00%MCUJFMedicure0.00%-17.37%-16.08%-16.15%-17.73%UMRXCogent Biosciences0.00%0.00%0.00%+10.70%+384.91%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPVOAptevo Therapeutics 2.33HoldN/AN/ACRPOFCeapro 0.00N/AN/AN/AGHSIGuardion Health Sciences 0.00N/AN/AN/AMCUJFMedicure 0.00N/AN/AN/AUMRXCogent Biosciences 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest APVO, CRPOF, MCUJF, GHSI, and UMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/15/2026APVOAptevo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)5/26/2026APVOAptevo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)5/8/2026APVOAptevo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E) ➝ Sell (E+)4/24/2026APVOAptevo Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (E+) ➝ Sell (E)(Data available from 6/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPVOAptevo TherapeuticsN/AN/AN/AN/A$17.42 per shareN/ACRPOFCeapro$7.14M1.86$0.06 per share2.74$0.32 per share0.53GHSIGuardion Health Sciences$12.25M0.35$0.14 per share23.15$6.39 per share0.50MCUJFMedicure$20.65M0.34N/AN/A$0.89 per share0.76UMRXCogent Biosciences$22.50M69.74N/AN/A$1.04 per share35.53Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPVOAptevo Therapeutics-$25.97M-$197.60N/AN/AN/AN/A-198.50%-117.06%8/10/2026 (Estimated)CRPOFCeapro-$3.49M-$0.06N/AN/AN/A-69.60%-20.30%-18.07%N/AGHSIGuardion Health Sciences$160K$4.870.66N/AN/A22.79%-73.69%-48.17%N/AMCUJFMedicure-$5.08M-$0.47N/AN/AN/A-21.65%-44.34%-26.22%8/26/2026 (Estimated)UMRXCogent Biosciences-$31.83M-$1.04N/AN/AN/A-96.84%-87.78%-52.14%N/ALatest APVO, CRPOF, MCUJF, GHSI, and UMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026MCUJFMedicure-$0.0439-$0.03+$0.0139$999.00$3.63 million$5.79 million5/13/2026Q1 2026APVOAptevo Therapeutics-$6.41-$6.41N/A-$6.41N/AN/A4/23/2026Q4 2025MCUJFMedicure-$0.0439-$0.29-$0.2462$999.00$3.62 million$6.13 million3/26/2026Q4 2025APVOAptevo Therapeutics-$8.10$118.23+$126.33$118.23N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAPVOAptevo TherapeuticsN/AN/AN/AN/AN/ACRPOFCeaproN/AN/AN/AN/AN/AGHSIGuardion Health Sciences$5.00155.28%N/A102.67%N/AMCUJFMedicureN/AN/AN/AN/AN/AUMRXCogent BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPVOAptevo TherapeuticsN/A3.363.36CRPOFCeaproN/A11.007.72GHSIGuardion Health SciencesN/A16.6816.59MCUJFMedicure0.031.040.73UMRXCogent Biosciences0.182.902.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPVOAptevo Therapeutics8.06%CRPOFCeaproN/AGHSIGuardion Health Sciences20.21%MCUJFMedicureN/AUMRXCogent Biosciences26.39%Insider OwnershipCompanyInsider OwnershipAPVOAptevo Therapeutics0.08%CRPOFCeaproN/AGHSIGuardion Health Sciences1.32%MCUJFMedicure12.90%UMRXCogent Biosciences31.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPVOAptevo Therapeutics501.25 million1.25 millionNot OptionableCRPOFCeaproN/A78.29 millionN/ANot OptionableGHSIGuardion Health Sciences101.35 million1.33 millionNot OptionableMCUJFMedicureN/A10.44 million9.09 millionNot OptionableUMRXCogent Biosciences7242.47 millionN/ANot OptionableAPVO, CRPOF, MCUJF, GHSI, and UMRX HeadlinesRecent News About These CompaniesCogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 ...May 30, 2026 | markets.businessinsider.comCogent Bio granted FDA priority review for lead asset in tumor indicationMay 28, 2026 | seekingalpha.comCogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO ...April 21, 2026 | markets.businessinsider.comCogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)April 1, 2026 | markets.businessinsider.comCogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)March 16, 2026 | markets.businessinsider.comCogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 BreakthroughFebruary 17, 2026 | fool.comCogent Biosciences submits NDA for bezuclastinib in NONADVSMDecember 30, 2025 | msn.comCogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic MastocytosisDecember 30, 2025 | tmcnet.comCogent Biosciences: Time For A PauseDecember 15, 2025 | seekingalpha.comCogent Biosciences price target raised to $48 from $45 at JefferiesDecember 8, 2025 | msn.comCogent Biosciences jumps after strong late-stage results in advanced systemic mastocytosisDecember 8, 2025 | msn.comCogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)December 8, 2025 | markets.businessinsider.comCogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American ...December 6, 2025 | tmcnet.comHC Wainwright & Co. Maintains Cogent Biosciences (COGT) Buy RecommendationNovember 14, 2025 | msn.comCogent Biosciences price target raised to $50 from $21 at H.C. WainwrightNovember 13, 2025 | msn.comCogent Biosciences’ phase 3 PEAK trial marks an advance in the treatment of gastrointestinal stromal tumors.November 13, 2025 | managedhealthcareexecutive.comMCogent Biosciences’ phase 3 PEAK trial marks an advance in the treatment of gastrointestinal stromal tumors.November 13, 2025 | managedhealthcareexecutive.comMCogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes ...November 11, 2025 | caledonianrecord.comCCogent Hits ‘Unprecedented’ Efficacy in Rare Stomach Cancer, Clearing Path to FDANovember 11, 2025 | biospace.comBCogent Biosciences Stock Surges 136%. Investors See Promise in Its Cancer Drug.November 10, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPVO, CRPOF, MCUJF, GHSI, and UMRX Company DescriptionsAptevo Therapeutics NASDAQ:APVO$4.67 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$4.65 -0.02 (-0.41%) As of 06/18/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company's lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.Ceapro OTCMKTS:CRPOF$0.17 0.00 (0.00%) As of 06/6/2024Ceapro Inc., a biotechnology company, engages in the development and marketing of health and wellness products and technology relating to plant extracts in the United States, Germany, China, Canada, and internationally. The company is involved in the development of proprietary extraction technologies and the application of these technologies to the production, development, and commercialization of active ingredients, such as oat beta glucan and avenanthramides, which are derived from oats and other renewable plant resources for healthcare and cosmetic industries. It also offers natural active ingredients, including oat powder, oat oil, oat peptides, and lupin peptides to the personal care, cosmetic, medical, and animal health industries; anti-aging skincare products to the cosmeceutical industries; and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner. The company has a research collaboration with the Angiogenesis Foundation. The company was incorporated in 1997 and is headquartered in Edmonton, Canada.Guardion Health Sciences NASDAQ:GHSIGuardion Health Sciences, Inc., a clinical nutrition company, develops and distributes clinically supported dietary supplements and medical foods in North America, Europe, and internationally. The company offers GlaucoCetin, a dietary supplement to support mitochondrial function with additional antioxidants to help reduce oxidative stress and increase blood flow throughout the body for enhanced eye support and ocular health; and Lumega-Z, a medical food that replenishes and restores the macular protective pigment. It also provides Viactiv Omega Boost Gel Bites, an omega-3 fish oil dietary supplement. The company distributes medical foods products through e-commerce website, guardionhealth.com. Guardion Health Sciences, Inc. was founded in 2009 and is headquartered in Houston, California.Medicure OTCMKTS:MCUJF$0.67 0.00 (0.00%) As of 06/18/2026Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.Cogent Biosciences NASDAQ:UMRXCogent Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer. The firm's technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/15 - 06/19 Applied Materials Stock Looks Pricey—Can AI Demand Justify the Rally? Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
